{"preliminary_commentary":{"by_channel":{"youtube":52,"podcast":25,"x_thread":23,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04680052\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tafasitamab"]],"indication":"relapsed/refractory follicular lymphoma or marginal zone lymphoma","name":"InMIND","nct_id":"NCT04680052","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=inmind-nct04680052. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"InMIND","arms":[{"description":"Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)","label":"Arm A : tafasitamab + rituximab + lenalidomide","type":"EXPERIMENTAL"},{"description":"Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)","label":"Arm B : placebo+rituximab+lenalidomide","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-08-09","type":"ESTIMATED"},"conditions":["Follicular Lymphoma","Marginal Zone Lymphoma"],"enrollment":{"count":654,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tafasitamab","otherNames":["INCMOR00208","MOR00208"],"type":"DRUG"},{"name":"rituximab","otherNames":[],"type":"DRUG"},{"name":"lenalidomide","otherNames":[],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-04","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First","timeFrame":"up to approximately 34 months"},{"measure":"FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First","timeFrame":"up to 2 years"}],"references":[{"citation":"Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M; inMIND Study team. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet. 2026 Jan 10;407(10524):133-146. doi: 10.1016/S0140-6736(25)01778-7. Epub 2025 Dec 5.","pmid":"41360064","type":"DERIVED"}],"start_date":{"date":"2021-04-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.","url":"https://clinicaltrials.gov/study/NCT04680052"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/inmind-nct04680052"}